Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada... see more

Bullboard (TSX:GUD)

View:
Post by gudisgoodon Nov 09, 2023 4:30am

Buybacks

During the past three months, GUD has bought back around 2.4 million shares. Relative to outstanding shares, this is the highest pace for buybacks we've had. If my numbers are correct:  ...more  
Comment by MrMugsyon Oct 29, 2023 3:23pm

RE:Jeff Martens

If I were to guess - and only a guess ... There is a very high level of expectation from Management.  There is nowhere to hide and you must always be at the top of your game. You are either ...more  
Post by gudisgoodon Oct 27, 2023 10:28am

Jeff Martens

As we discussed earlier, mr. Martens was absent from the previous earnings call. Sure enough, according to LinkedIn, his time at Knight ended in June 2023. Whatever happened there? A quiet exit for ...more  
Post by chechingon Oct 16, 2023 9:15pm

Minjuvi

Good News for Brasil, this new drug is promising in the way that it seem to bring diverse use for multiple diseases.  On the Incyte website you can also see that the treatment is submited to ...more  
Post by GoldenInvestoron Oct 16, 2023 5:11am

Weight loss drugs

If novo nordisk , & Eli Lilly & other weight loss drugs prove safe & healthy long term, do these companies have a network in South America ? Do u think our South American distro network ...more  
Post by Possibleidiot01on Oct 14, 2023 1:54pm

5i Research

Review of Knight Therapeutics Sep 21, 2023 The share price of GUD has declined over the years, while its fundamentals have been mixed. The company maintains a very strong balance sheet and has ...more  
Comment by Stockoman1on Oct 14, 2023 6:20am

RE:RE:57.08 % shares held In tight hands- sharecount shrinks

Longrun said        " I am looking forward to meaningful updates from Management over the coming quarters about profitability!  "    AMEN !
Post by GoldenInvestoron Oct 13, 2023 9:44am

Larry fink bullish on healthcare and living longer

Discussing great opportunities in Health care innovation and  growth opportunities in Mexico , amongst others  - & Great for companies in this area - on CNBC
Comment by longrun86on Oct 08, 2023 11:15am

RE:57.08 % shares held In tight hands- sharecount shrinks

It's always nicer to be in business with "owners" of the company compared to fair-weather "renters". Ultimately though, the return profile based on the capital invested is too ...more  
Post by GoldenInvestoron Oct 06, 2023 7:54pm

57.08 % shares held In tight hands- sharecount shrinks

14.24 held by institutions 42.84% held by insiders   57.08 % shares held   also, unsure if these numbers include the buybacks/cancellations, which would just increase their ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities